For decades, the standard first-line treatment for Acute Myeloid Leukemia has been the intensive “7+3” chemotherapy regimen, which combines cytarabine with an anthracycline drug. However, experts such as Richard Stone say the dominance of this approach is gradually fading as new targeted and less toxic therapies become available. One major challenger is the combination of Azacitidine and Venetoclax, which was originally developed for older or less-fit patients but is now showing promising results in younger individuals as well.
Recent data from the PARADIGM Trial reported in December 2025 found that azacitidine plus venetoclax improved event-free survival and produced fewer side effects compared with the traditional 7+3 regimen, while overall survival remained similar. In current clinical practice, 7+3 is also less commonly used alone. Physicians often combine it with targeted therapies, including drugs that inhibit the FLT3 mutation or the antibody-drug conjugate Gemtuzumab Ozogamicin.
Treatment decisions are increasingly based on both patient health and the genetic profile of the leukemia. Factors such as age, other medical conditions, and mutations like FLT3 or NPM1 help guide therapy choices. Researchers are also exploring new strategies, including triplet drug combinations and emerging menin inhibitors targeting KMT2A-related disease, which could further shift AML care away from traditional intensive chemotherapy.